González de Aledo, ManuelCañizares, AngelinaVázquez-Rodríguez, PilarCastro-Iglesias, ÁngelesMoldes, LuzLópez, SoledadMiguez, EnriqueBou, GermánMena, Álvaro2024-10-142024-10-142022González de Aledo M, Cañizares A, Vázquez-Rodríguez P, Castro Á, Moldes L, López S, Míguez E, Bou G, Mena Á. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV. AIDS. 2022 Apr 1;36(5):691-695.0269-9370http://hdl.handle.net/2183/39592Concise communication[Abstract] Objective: To evaluate the safety and the serological response after two doses of mRNA-based SARS-CoV-2 vaccination in people with HIV (PWH). Methods: Participants were evaluated 4 weeks after the second dose of mRNA-1273 or BNT162b2 vaccine. Tolerability was evaluated with a specific adverse event questionnaire. Patient's sera were analysed using LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin). Results: One-hundred PWH were included, 75% of them men, with a mean age of 44 ± 11 years old, all receiving antiretroviral treatment and mostly with controlled viral loads (98% with HIV RNA <50 copies/ml) and 96% had >200 CD4+/μl. All patients seroconverted after vaccination (antibody concentration ≥33.8 binding antibody units [BAU]/ml). Only 3% of the patients had a low antibody concentration (<520 BAU/ml), whereas 67% of them had concentrations above the assay's detection range (>2080 BAU/ml). Fifty-six patients had local or systemic symptoms, with mild arthromyalgia being the most common systemic symptom. No severe adverse events were reported. Conclusions: Vaccination with two doses of mRNA-1273 or BNT162b2 is well tolerated in PWH under effective antiretroviral treatment and it leads to a successful antibody response.engCoronavirus disease 2019HIVmRNA vaccineSARS-CoV-2journal articleopen access10.1097/QAD.0000000000003161